Timothy Walbert - Horizon Pharma Chairman, CEO and Pres
Chairman
Mr. Timothy P. Walbert is Chairman of the Board, President, Chief Executive Officer of the Company. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, Mr. Walbert served as executive vice president, commercial operations of NeoPharm, Inc., a public biopharmaceutical company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multiindication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. Mr. Walbert also serves as chairman of the board of directors of Egalet Corporationrationration, a public pharmaceutical company. Mr. Walbert sits on the board of directors of the Illinois Biotechnology Innovation Organization, the Biotechnology Innovation Organization, World Business Chicago and the Greater Chicago Arthritis Foundation. Mr. Walbert is also a member of the Illinois Innovation Council. Mr. Walbert previously served on the board of directors of Raptor Pharmaceutical Corporationration, a public biopharmaceutical company, from 2010 to 2014 XOMA Corporationrationration, a public biotechnology company, from 2010 to 2017 and Sucampo Pharmaceuticals, Inc., a public biopharmaceutical company, from March 2016 to February 2018 since 2010.
| Age | 56 |
| Tenure | 15 years |
| Phone | 353 1 772 2100 |
| Web | https://www.horizontherapeutics.com |
Timothy Walbert Latest Insider Activity
Tracking and analyzing the buying and selling activities of Timothy Walbert against Horizon Pharma stock is an integral part of due diligence when investing in Horizon Pharma. Timothy Walbert insider activity provides valuable insight into whether Horizon Pharma is net buyers or sellers over its current business cycle. Note, Horizon Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Horizon Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Timothy Walbert over a year ago Acquisition by Timothy Walbert of 7000 shares of XOMA Corp subject to Rule 16b-3 | ||
Timothy Walbert over a year ago Exercise or conversion by Timothy Walbert of 2800 shares of XOMA Corp subject to Rule 16b-3 |
Horizon Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0444 % which means that it generated a profit of $0.0444 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0854 %, meaning that it created $0.0854 on every $100 dollars invested by stockholders. Horizon Pharma's management efficiency ratios could be used to measure how well Horizon Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Horizon Pharma PLC currently holds 2.56 B in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Horizon Pharma PLC has a current ratio of 3.88, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Horizon Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| Alex Gorsky | Johnson Johnson | 64 | |
| Jennifer Taubert | Johnson Johnson | 61 | |
| Ashley McEvoy | Johnson Johnson | 50 | |
| Daniel Vasella | Novartis AG ADR | 65 | |
| Paulus Stoffels | Johnson Johnson | 57 | |
| Kenneth Frazier | Merck Company | 67 | |
| Enrico Vanni | Novartis AG ADR | 70 | |
| Daniel ODay | Gilead Sciences | 60 | |
| Robert Bradway | Amgen Inc | 62 | |
| Robert Michael | AbbVie Inc | 55 | |
| Alex Krauer | Novartis AG ADR | 69 | |
| Leif Johansson | AstraZeneca PLC ADR | 68 | |
| Joerg Reinhardt | Novartis AG ADR | 65 | |
| Joaquin Duato | Johnson Johnson | 62 | |
| Carlos Alban | AbbVie Inc | 55 | |
| Robert JD | Merck Company | 58 | |
| Thibaut Mongon | Johnson Johnson | 51 | |
| Giovanni Caforio | Bristol Myers Squibb | 56 | |
| Richard Gonzalez | AbbVie Inc | 71 | |
Management Performance
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 |
Horizon Pharma PLC Leadership Team
Elected by the shareholders, the Horizon Pharma's board of directors comprises two types of representatives: Horizon Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Horizon. The board's role is to monitor Horizon Pharma's management team and ensure that shareholders' interests are well served. Horizon Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Horizon Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jane Gonnerman, Office Staff | ||
| Sean JD, Exec Counsel | ||
| Timothy Walbert, Chairman, CEO and Pres | ||
| Tina Ventura, Senior Vice President Investor Relations | ||
| Patrick McIlvenny, VP Officer | ||
| Paul Hoelscher, CFO and Executive VP of Fin. | ||
| FACP FACP, Ex Officer | ||
| Andy Pasternak, Ex Officer | ||
| Aaron Cox, Exec CFO | ||
| Geoffrey Curtis, Senior Vice President - Corporate Communications |
Horizon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Horizon Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0854 | |||
| Return On Asset | 0.0444 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 26.87 B | |||
| Shares Outstanding | 229 M | |||
| Shares Owned By Insiders | 1.18 % | |||
| Shares Owned By Institutions | 98.82 % | |||
| Number Of Shares Shorted | 7.1 M | |||
| Price To Earning | 32.55 X |
Pair Trading with Horizon Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Horizon Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Horizon Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Expedia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Expedia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Expedia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Expedia Group to buy it.
The correlation of Expedia is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Expedia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Expedia Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Expedia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Horizon Stock
If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |